I<sub>f</sub>电流抑制剂伊伐布雷定在心血管疾病中的临床应用进展

李景东; 甘婷

doi:10.13201/j.issn.1001-1439.2020.03.004

I_f电流抑制剂伊伐布雷定在心血管疾病中的临床应用进展

李景东^,,
甘婷

- 1 华中科技大学同济医学院附属协和医院心内科(武汉, 430022)
基金项目:
国家自然科学基金项目(No:81873476)

详细信息

通讯作者: 李景东,E-mail:jingdong-li@mail.hust.edu.cn

中图分类号: R54

收稿日期: 2020-03-03

The clinical application of I_f current inhibitor ivabradine

LI Jingdong^,,
GAN Ting

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: LI Jingdong, E-mail: jingdong-li@mail.hust.edu.cn

Received Date: 03 March 2020

摘要

摘要: 伊伐布雷定通过选择性抑制超极化激活环核苷酸门控阳离子通道(HCN)介导的I_f电流,降低窦房结4期自动去极化速率而减慢心率。此外,伊伐布雷定还能通过降低心率来改善心肌能量供应,预防心脏重构并改善远期预后,目前在心力衰竭、冠心病心绞痛和不适当窦性心动过速三方面具有明确的治疗作用。本文仅就伊伐布雷定的电生理作用特点及其在临床应用中的重要研究进展作扼要介绍。
- If电流抑制剂 /
- 伊伐布雷定 /
- 冠心病 /
- 心力衰竭 /
- 心律失常
Abstract: Ivabradine can selectively inhibit I_f current by mediating hyperpolarization-activated cyclic nucleotide gated cation(HCN) channel,resulting in the decreased rate of phase 4 automatic depolarization in the sinoatrial node and consequently,the heart rate.Recent studies have found that ivabradine can not only improve myocardial energy supply by lowering heart rate,but also prevent heart remodeling and improve long-term prognosis.Currently,ivabradine has definite therapeutic effect on heart failure,angina pectoris and inappropriate sinus tachycardia.Here,we aim to introduce the electrophysiological mechanisms of action of ivabradine and the progress of salient studies that lead to its current clinical use.
- If current inhibitor /
- Ivabradine /
- coronary artery disease /
- heart failure /
- arrhythmia

HTML全文

参考文献(12)

[1]	Koruth J S,Lala A,Pinney S,et al.The Clinical Use of Ivabradine[J].J Am Coll Cardiol,2017,70(14):1777-1784.
[2]	Difrancesco D.The role of the funny current in pacemaker activity[J].Circ Res,2010,106(3):434-446.
[3]	Tardif J C,Ford I,Tendera M,et al.Efficacy of ivabradine,a new selective I(f) inhibitor,compared with atenolol in patients with chronic stable angina[J].Eur Heart J,2005,26(23):2529-2536.
[4]	Fox K,Ford I,Steg P G,et al.Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a randomised,double-blind,placebo-controlled trial[J].Lancet,2008,372(9641):807-816.
[5]	Tardif J C,Ponikowski P,Kahan T.Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy:a 4-month,randomized,placebo-controlled trial.European heart journal [J].2009,30(5):540-548.
[6]	Fox K,Ford I,Steg PG,et al.Ivabradine in stable coronary artery disease without clinical heart failure.The New England journal of medicine[J].2014,371(12):1091-1099.
[7]	Werdan K,Ebelt H,Nuding S,et al.Ivabradine in Combination with Metoprolol Improves Symptoms and Quality of Life in Patients with Stable Angina Pectoris:A post hoc Analysis from the ADDITIONS Trial[J].Cardiology,2016,133(2):83-90.
[8]	Zugck C,Martinka P,Stöckl G.Ivabradine treatment in a chronic heart failure patient cohort:symptom reduction and improvement in quality of life in clinical practice.Advances in therapy [J].2014,31(9):961-974.
[9]	Gupta A,Sharma YP.Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376(9758):875-885.
[10]	Komajda M,Isnard R,Cohen-Solal A,et al.Effect of ivabradine in patients with heart failure with preserved ejection fraction:the EDIFY randomized placebo-controlled trial[J].Eur J Heart Fail,2017,19(11):1495-1503.
[11]	Hidalgo FJ,Anguita M,Castillo JC,et al.Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF):A randomised study[J].Int J Cardiol,2016,217:7-11.
[12]	Cappato R,Castelvecchio S,Ricci C,et al.Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia:a prospective,randomized,placebo-controlled,double-blind,crossover evaluation[J].J Am Coll Cardiol,2012,60(15):1323-1329.